Benchtalk Boston 2025 Event Brief
Benchling hosted over 500 participants – including customers, partners, prospects and analysts at Benchtalk 2025 Boston, its annual industry event showcasing the company’s innovation roadmap and customer successes. The event reinforced Benchling’s continued evolution from a research-centric platform to one that spans development and GxP-regulated environments, asserting its position at the center of the connected digital lab ecosystem now with AI capabilities.
Benchling leadership framed this expansion as a natural progression of its mission to connect data, automation, and intelligence across the scientific lifecycle. “The Future of biotech depends on bringing discovery and development closer together,” said Shawna Wolverton, Chief Product Officer in a recent press release. The company’s Development offering now supports process characterization, analytical method development and execution, giving scientists and engineers shared access to structured data and standardized workflows that accelerate development timelines.
Artificial intelligence (AI) took center stage throughout the event. Benchling presented its strategy for integrating AI and agentic capabilities directly into its platform, emphasizing secure, role-based applications that operate within existing permission frameworks. The company positioned its AI suite not as a standalone layer but as an enabler of automation, insight generation and faster iteration – particularly as the market pushes for compressing timelines from the traditional 10-15 years to as little as 7-10. (See: Accelerating Time To Market with Biopharma PLM)
A highlight of the conference was a case study presented by Amgen, which offered a practical view of digital maturity within a complex, global enterprise. Michelle Hortter, Associate Director, and Timin Hadi, Director, R&D Informatics, outlined Amgen’s phased rollout of Benchling as they transitioned away from legacy systems that could no longer scale with increased throughput and modality expansion. The effort required rethinking their data model to ensure consistent, structured data entry, traceability and dashboard-based monitoring of turnaround times and compliance.
The fireside chat between Benchling CEO, Sajith Wickramasekara, and Blueprint Medicines CEO, Kate Haviland, offered a candid discussion on strategic growth, innovation and leadership in biotech. The pair reflected on the importance of cultivating strong teams, aligning mission and culture early in a company’s trajectory, and how M&A strategy starts with building organizations that others want to acquire. Haviland emphasized Blueprint’s decision to pivot from oncology to rare diseases as a defining leadership moment, while both leaders reinforced that innovation thrives when vision, science and culture advance together.
The event also recognized several organizations driving meaningful change in life sciences through the Benchling Changemaker Awards, including Life Edit Therapeutics (an ElevateBio company), Go2 Software, Umoja Biopharma, Moderna’s Digital Team and Bristol Myers Squibb.
In Brief
Benchling’s continued development of extensible APIs, structured workflows and integrated analytics reflects its intent to unify research, development and GxP-regulated environments under a single data foundation. Benchtalk 2025 Boston event illustrated that the company’s platform, and its community, are moving steadily toward their vision, to be a key enabler of the next chapter in scientific digital transformation.
Related Content:
- How Biopharma is Digitally Transforming to Accelerate Development
- Accelerating the Trajectory of Digital Sustainability in the Lab
- Is Your Lab Ready for the FDA’s Remote Data Access Era?
- Sapio Introduces The Electronic Notebook That Thinks Like A Scientist
Stay Connected with Axendia!
Stay at the forefront of innovation and technology in life sciences, healthcare, and space-enabled research by connecting with Axendia.
- Follow us on LinkedIn: Join our professional network and stay updated on the latest insights, trends, and case studies. Connect with Axendia on LinkedIn
- Subscribe to Our Updates: Get exclusive insights and thought leadership articles delivered straight to your inbox. Sign up for our newsletter
- Share Your Thoughts: We’d love to hear from you! Contact us to discuss your ideas, challenges, or opportunities. Email Axendia
Let’s drive innovation together!
Ready to unlock new opportunities and drive success? Schedule an Analyst Inquiry
The opinions and analysis expressed in this post reflect the judgment of Axendia at the time of publication and are subject to change without notice. Information contained in this post is current as of publication date. Information cited is not warranted by Axendia but has been obtained through a valid research methodology. This post is not intended to endorse any company or product and should not be attributed as such.